Correction to: Triamcinolone Aceonide Extended-Release: A Review in Osteoarthritis Pain of the Knee

1 Correction to: Drugs (2019) 79:455–462 https://doi.org/10.1007/s40265-019-01083-3

An Online First version of this article was made available online at https://rd.springer.com/article/10.1007/s40265-019-01083-3 on the 8th of March 2019. Two errors were identified in the article; please note the following:

• 1. Page 456, Column 2, Paragraph 1, Lines 2–7: The following sentence, which previously read:

  
  

  “Both triamcinolone acetonide ER 40 mg and triamcinolone acetonide CS 40 mg were associated with significant reductions in 24 h weighted mean serum cortisol (maximum reduction within 24 h of administration of 42.7 vs. 59.0%) and 24 h urinary cortisol excretion (43.8 vs. 58.5%) from baseline.”

  
  

  Should read:

  
  

  “Both triamcinolone acetonide ER 32 mg and triamcinolone acetonide CS 40 mg were associated with significant reductions in 24 h weighted mean serum cortisol (maximum reduction within 24 h of administration of 42.7 vs. 59.0%) and 24 h urinary cortisol excretion (43.8 vs. 58.5%) from baseline.”

• 2. Page 457, Column 1, Paragraph 1, Lines 12–14: The following sentence, which previously read:

  
  

  “By contrast, the mean concentration of triamcinolone acetonide ER 6 weeks after treatment with 1 mL triamcinolone acetonide CS 40 mg was 0.0077 ng/mL [24].”

  
  

  Should read:

  
  

  “By contrast, the mean concentration of triamcinolone acetonide 6 weeks after treatment with 1 mL triamcinolone acetonide CS 40 mg was 0.0077 ng/mL [24].”